ArticleJournal of intellectual disability research : JIDR2026
Antipsychotic Use Among Intellectually Disabled Individuals With Rare Genetic Variants That Confer Risk for Schizophrenia.
Article in Journal of intellectual disability research : JIDR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRare genetic variation can predispose individuals to the development of schizophrenia, with certain genes and copy number variants (CNVs) conferring risk at the exome/genome-wide level. Despite this strong association, little is known about antipsychotic effectiveness and tolerability among individuals with most of these disorders. As such, this retrospective chart review sought to gather more data regarding the real-world use of antipsychotics in this context.
methodsThis largely descriptive, cross-sectional and retrospective chart review took place at a developmental disabilities mental health clinic. Clinical information was primarily derived from electronic medical records. Individuals with a history of psychosis and antipsychotic exposure identified as having a genetic variant known to confer exome/genome-wide risk for schizophrenia were included in the study.
resultsOf the 1196 charts reviewed, 24 individuals with a relevant genetic variant were identified, 11 of whom had experienced psychotic symptoms that were treated with antipsychotic medication. Six have 22q11.2 deletion syndrome, two have 15q11-q13 duplication syndrome and one individual each has a 16p11.2 duplication, a 7q11.23 duplication and a missense variant in TRIO. Overall, antipsychotic therapy tended to be reasonably effective and well tolerated (particularly among those individuals who do not have 22q11.2 deletion syndrome), despite side effects of some kind occurring in most cases.
conclusionWhile this study had numerous limitations that prevent firm conclusions from being drawn, it provides preliminary evidence that antipsychotics may be relatively safe and effective in at least some of the genetic disorders most strongly associated with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.